# Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer

> **NCT02993094** · PHASE1,PHASE2 · TERMINATED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 31 (actual)

## Conditions studied

- Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02993094
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-21
- **Primary completion:** 2020-08-15
- **Final completion:** 2020-08-15
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Due to slow recruitment, the study had to be terminated prematurely.
- **Last updated:** 2020-11-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02993094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02993094, "Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02993094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*